News on lab-developed tests and emerging diagnostic technologies.
The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.
The researchers will compare saliva and plasma samples from 50 patients with non-small cell lung cancer to identify circulating tumor DNA in saliva.
The firm also announced the amendment of the terms of a loan with CRG, a global healthcare investor.
The firm's molecular diagnostics revenues rose 315 percent due to COVID-19 testing demand.
The test uses primers and probes from Thermo Fisher Scientific's authorized TaqPath COVID-19 Combo Kit with a modified results interpretation algorithm.
